Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Credit

<ul><li>CVS Health has managed to outperform the management's financial targets and has capitalized on the pandemic situation to the best of its ability.</li><li>Its pharmacy services segment revenues increased 8.2% year over year in 2021, owing to increased pharmacy claims volume, specialty pharmacy growth, and brand inflation, partially offset by the impact of continued client price improvements.</li><li>Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.</li></ul>

CVS Health has managed to outperform the management's financial targets and has capitalized on the pandemic situation to the best of its ability.Its pharmacy services segment revenues increased 8.2% year over year in 2021, owing to increased pharmacy claims volume, specialty pharmacy growth, and brand inflation, partially offset by the impact of continued client price improvements.Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

CVS Health: Detailed Credit Analysis & Financial Strength Evaluation Report

Equity Capital Markets

Walgreens Boots Alliance / Equity Capital Markets

<ul><li>CVS Health and Walgreens Boots Alliance are two of the largest pharmacy chains in the world.</li><li>Both these companies have done their fair share of diversification with CVS Health venturing into clinics and telehealth whereas Walgreens ventured into the cosmetics retail and other domains.</li><li>The retail space is traditionally known to have low revenue multiples and both these companies are no exceptions to this rule.</li></ul>

CVS Health and Walgreens Boots Alliance are two of the largest pharmacy chains in the world.Both these companies have done their fair share of diversification with CVS Health venturing into clinics and telehealth whereas Walgreens ventured into the cosmetics retail and other domains.The retail space is traditionally known to have low revenue multiples and both these companies are no exceptions to this rule.

CVS Health vs. Walgreens Boots Alliance - The Battle Of The Pharmacy Majors

<ul><li>CVS had another strong quarter surpassing Wall Street expectations as it continued to witness a robust demand for COVID-19 tests and vaccines, administered at its pharmacies and clinics.</li><li>This demand might be slower in the latter half of 2021 but the Delta variant could be an important factor that could benefit the company.</li><li>The company witnessed a double-digit growth in almost all its segments but Covid-related costs did weigh upon its Aetna health insurance unit.</li></ul>

CVS had another strong quarter surpassing Wall Street expectations as it continued to witness a robust demand for COVID-19 tests and vaccines, administered at its pharmacies and clinics.This demand might be slower in the latter half of 2021 but the Delta variant could be an important factor that could benefit the company.The company witnessed a double-digit growth in almost all its segments but Covid-related costs did weigh upon its Aetna health insurance unit.

Silver Point

Thomas J. Monaco

Independent Insight Provider

Silver Point is a boutique research firm that focuses on the broader financial services sector, with a particular focus on troubled institutions globally. 

Asia Ex Japan

Equity Bottom-Up

*Major US Merchant Deal: Tencent Holding’s (700.HK) [Tencent] Afterpay Touch's (APT.AU) [Afterpay] recently announced that it is further expanding its Buy Now, Pay Later (BNPL) model to several major high profile US merchants in order to boost sales and margins. Afterpay is now allowing all US users to shop at 13 retailers by October 2021 - ahead of the holiday shopping season; and*Tencent’s Midas Touch: Tencent continues to hit it out of the park with its Afterpay stake. In addition to its superb return on investment over the past ten months since the stake announcement - -even after giving back some of its gains, this alliance with Australia’s premier financial technology BNPL company is paying dividends to Tencent in numerous other ways.

*Major US Merchant Deal: Tencent Holding’s (700.HK) [Tencent] Afterpay Touch's (APT.AU) [Afterpay] recently announced that it is further expanding its Buy Now, Pay Later (BNPL) model to several major high profile US merchants in order to boost sales and margins. Afterpay is now allowing all US users to shop at 13 retailers by October 2021 - ahead of the holiday shopping season; and*Tencent’s Midas Touch: Tencent continues to hit it out of the park with its Afterpay stake. In addition to its superb return on investment over the past ten months since the stake announcement - -even after giving back some of its gains, this alliance with Australia’s premier financial technology BNPL company is paying dividends to Tencent in numerous other ways. 

Tencent Holdings – Digging In Their Heals

Alpha-Centric ESG Research

Kyle Rudden

The Biden-Harris administration recently announced four "Day One" priorities, the first of which is their COVID-19 response plan. COVID-19 response is first, because it is a prerequisite to economic recovery, which is the second of their four "Day One" priorities.Several investment themes are inherent in Biden's COVID-19 plan, some more direct and obvious than others. This Insight overviews more significant themes and their most representative stocks, in three sections (the first two will be expanded on in separate upcoming reports):<ol>
<li>
COVID-19 Testing: Testing is the largest, most tangible, nearest-term investment opportunity created by Biden's plan. An estimated US$75-100 billion for testing could be windfall for certain stocks, but not all. Selectivity is key, and timing is critical (related to vaccine development).</li>
<li>
Vaccine Delivery: Biden's plan emphasises vaccine manufacturing and delivery, versus vaccine development (Trump had allocated <a href="https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html" target="_blank" rel="noopener">billions</a> to vaccine development companies). Some might go to big pharma companies for M&amp;D, but most should benefit other "cold chain" stocks.</li>
<li>
PPE Supply/Other: PPE manufacturing, of course, but that is largely old news. I will address it, but do so along with other more interesting collateral themes. For example, retail drugs chains, elder-care, medical technologies, and a few other related industries.</li>
</ol>

The Biden-Harris administration recently announced four "Day One" priorities, the first of which is their COVID-19 response plan. COVID-19 response is first, because it is a prerequisite to economic recovery, which is the second of their four "Day One" priorities.Several investment themes are inherent in Biden's COVID-19 plan, some more direct and obvious than others. This Insight overviews more significant themes and their most representative stocks, in three sections (the first two will be expanded on in separate upcoming reports):

COVID-19 Testing: Testing is the largest, most tangible, nearest-term investment opportunity created by Biden's plan. An estimated US$75-100 billion for testing could be windfall for certain stocks, but not all. Selectivity is key, and timing is critical (related to vaccine development).

Vaccine Delivery: Biden's plan emphasises vaccine manufacturing and delivery, versus vaccine development (Trump had allocated billions to vaccine development companies). Some might go to big pharma companies for M&amp;D, but most should benefit other "cold chain" stocks.

PPE Supply/Other: PPE manufacturing, of course, but that is largely old news. I will address it, but do so along with other more interesting collateral themes. For example, retail drugs chains, elder-care, medical technologies, and a few other related industries.


Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes

United States

CVS Health Corporation is an integrated pharmacy health care provider. The Company's offerings include pharmacy benefit management services; mail order, retail and specialty pharmacy; disease management programs; and retail clinics. The company operates drugstores throughout the U.S., the District of Columbia, and Puerto Rico.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cvs Health Corp (CVS US)

CVS Health: Detailed Credit Analysis & Financial Strength Evaluation Report

CVS Health has managed to outperform the management's financial targets and has capitalized on the pandemic situation to the best of its...

Baptista Research

CVS Health vs. Walgreens Boots Alliance - The Battle Of The Pharmacy Majors

CVS Health and Walgreens Boots Alliance are two of the largest pharmacy chains in the world. Both these companies have done their fair share of...

Baptista Research

CVS Health Corp - Investment Thesis

CVS had another strong quarter surpassing Wall Street expectations as it continued to witness a robust demand for COVID-19 tests and vaccines,...

Baptista Research

Tencent Holdings – Digging In Their Heals

TENCENT HOLDINGS: Tencent' s Afterpay recently announced a further expansion of its BNPL model to several major US merchants in order to boost...

Thomas J. Monaco

Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes

Biden's recently-announced COVID-19 response plan suggests a number of investment themes. This Insight overviews the more significant of those...

Kyle Rudden

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)